ArticleCureus2026
Glutamatergic Enhancement Using As-Needed Dextromethorphan and Piracetam in a Stimulant-Partially Responsive Adult With ADHD: A Single-Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adults with attention-deficit/hyperactivity disorder (ADHD) frequently experience residual symptoms such as cognitive fatigue, brain fog, and reduced motivation despite optimized stimulant therapy. Emerging evidence points to disrupted dopamine-glutamate coupling and insufficient synaptic pruning as contributors to these persistent deficits, suggesting a potential role for glutamatergic modulation inspired by ketamine's rapid neuroplastic effects. This report describes a 25-year-old man with childhood-onset ADHD who, despite trials of high-dose methylphenidate (up to 72 mg) and lisdexamfetamine (up to 80 mg), continued to report daytime lethargy, mental sluggishness, irritability, and oversleeping while on moderate-dose extended-release methylphenidate (Concerta 36-54 mg daily). After several weeks of monotherapy yielding incomplete benefit, low-dose dextromethorphan (DXM, 30 mg as needed) and piracetam (600 mg as needed) were introduced on a pro re nata (PRN, as-needed) basis, primarily on workdays with higher cognitive demands. Within one week, the patient reported a marked and reproducible shift: elimination of afternoon tiredness, clearer thinking, reduced irritability, enhanced processing speed, and restored functional drive, with symptoms reverting on days the adjuncts were withheld. No significant adverse effects were noted. This single-case observation suggests that low-dose dextromethorphan, through brief N-methyl-D-aspartate modulation, combined with piracetam's α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) potentiation, may enhance methylphenidate's modest glutamate release, potentially promoting an AMPA-favorable plasticity state that could help mitigate pruning-related network inefficiencies often seen in adult ADHD. Carefully designed controlled studies are needed to better understand efficacy, optimal dosing, and long-term safety of such combinations (preliminary observation only).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.